Article Text

Download PDFPDF
Risk of Ovarian Cancer Relapse Score: A Prognostic Algorithm to Predict Relapse Following Treatment for Advanced Ovarian Cancer
  1. Ivana Rizzuto, MRCOG*,
  2. Chara Stavraka, MRes, MRCP*,
  3. Jayanta Chatterjee, MRCOG*,
  4. Jane Borley, PhD, MRCOG*,
  5. Thomas Glass Hopkins, MBBS*,,
  6. Hani Gabra, PhD, FRCP*,,
  7. Sadaf Ghaem-Maghami, PhD, MRCOG*,,
  8. Les Huson, PhD, CStat and
  9. Sarah P. Blagden, PhD, FRCP*,
  1. *Imperial College Healthcare NHS Trust, Garry Weston Cancer Centre, and
  2. Ovarian Cancer Action Research Centre, Hammersmith Hospital; and
  3. Division of Experimental Medicine, Imperial College London, Hammersmith Campus, London, United Kingdom.
  1. Address correspondence and reprint requests to Sarah P. Blagden, PhD, FRCP, Imperial College Healthcare NHS Trust, Garry Weston Cancer Centre and Ovarian Cancer Action Research Centre, Hammersmith Hospital, Du Cane Rd, London W12 0HS, United Kingdom. E-mail: s.blagden@imperial.ac.uk.

Abstract

Objective The aim of this study was to construct a prognostic index that predicts risk of relapse in women who have completed first-line treatment for ovarian cancer (OC).

Methods A database of OC cases from 2000 to 2010 was interrogated for International Federation of Gynecology and Obstetrics stage, grade and histological subtype of cancer, preoperative and posttreatment CA-125 level, presence or absence of residual disease after cytoreductive surgery and on postchemotherapy computed tomography scan, and time to progression and death. The strongest predictors of relapse were included into an algorithm, the Risk of Ovarian Cancer Relapse (ROVAR) score.

Results Three hundred fifty-four cases of OC were analyzed to generate the ROVAR score. Factors selected were preoperative serum CA-125, International Federation of Gynecology and Obstetrics stage and grade of cancer, and presence of residual disease at posttreatment computed tomography scan. In the validation data set, the ROVAR score had a sensitivity and specificity of 94% and 61%, respectively. The concordance index for the validation data set was 0.91 (95% confidence interval, 0.85-0.96). The score allows patient stratification into low (<0.33), intermediate (0.34–0.67), and high (>0.67) probability of relapse.

Conclusions The ROVAR score stratifies patients according to their risk of relapse following first-line treatment for OC. This can broadly facilitate the appropriate tailoring of posttreatment care and support.

  • CA-125
  • Ovarian cancer
  • Prognostic factors
  • Relapse
  • ROVAR

Statistics from Altmetric.com

Footnotes

  • This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.